Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights.

Autor:	Sujit SJ; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Aminu M; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karpinets TV; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen P; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Saad MB; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Salehjahromi M; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Boom JD; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Biomedical Engineering, Duke University, Durham, NC, USA., Qayati M; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., George JM; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA., Allen H; Natural Sciences, Rice University, Houston, TX, USA., Antonoff MB; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong L; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hu X; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Heeke S; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tran HT; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Le X; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Elamin YY; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Altan M; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vokes NI; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sheshadri A; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin J; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lu Y; Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Behrens C; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Godoy MCB; Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wu CC; Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chang JY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chung C; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Institute of Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jaffray DA; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Institute of Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vaporciyan AA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gibbons DL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Heymach J; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Lung Cancer Genomics Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Lung Cancer Interception Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cascone T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wu J; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwu11@mdanderson.org.; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwu11@mdanderson.org.; Institute of Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwu11@mdanderson.org.
Jazyk:	angličtina
Zdroj:	Nature communications [Nat Commun] 2024 Apr 11; Vol. 15 (1), pp. 3152. Date of Electronic Publication: 2024 Apr 11.
DOI:	10.1038/s41467-024-47512-0
Abstrakt:	While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), the independent contribution of quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains underexplored. In our multi-institutional study of 394 NSCLC patients, we utilize pre-treatment computed tomography (CT) and 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) to establish a habitat imaging framework for assessing regional heterogeneity within individual tumors. This framework identifies three PET/CT subtypes, which maintain prognostic value after adjusting for clinicopathologic risk factors including tumor volume. Additionally, these subtypes complement ctDNA in predicting disease recurrence. Radiogenomics analysis unveil the molecular underpinnings of these imaging subtypes, highlighting downregulation in interferon alpha and gamma pathways in the high-risk subtype. In summary, our study demonstrates that these habitat imaging subtypes effectively stratify NSCLC patients based on their risk levels for disease recurrence after initial curative surgery or radiotherapy, providing valuable insights for personalized treatment approaches. (© 2024. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink